ClinicalTrials.gg
RecruitingNCT07715682Updated Sep 16, 2026

The Effect of Gentle Human Touch and Stimulus Reduction on Pain and Comfort During Heel Blood Collection in Premature Newborns

An interventional study of Gentle Human Touch and Environmental Modification in Premature, Neonatal Intensive Care Unit and Touch, sponsored by Kubra Nur Kabakcı Sarıdağ. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 32 Weeks to 37 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Kubra Nur Kabakcı Sarıdağ · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
32 Weeks to 37 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Premature Birth with a site in Turkey — 44 open to participants now, 49 under way, none of them phase 3. Premature Birth · Turkey.

Planned enrollment
105th of 197
60 · median 64
Started
2026
with 18 others
No phase
192 of 247
39 open now
Primary completion
2026-09
later than 35 of 48 live
Registered
227th of 247
by date

Among the 247 studies in Premature Birth with a site in Turkey, this one is the 105th largest by planned enrollment of the 197 interventional ones that give a count, is one of 19 that started in 2026, is one of 192 with no phase, reaches primary completion later than 35 of the 48 other live ones, and was the 227th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

44 of the 247 studies in Premature Birth with a site in Turkey are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 32 Weeks to 37 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Premature Birth with a site in Turkey, or all of them as a file.
02

Study summary

Premature infants frequently experience painful procedures during their admission to neonatal intensive care units; this can lead to acute adverse events, imbalances, and long-term neurodevelopmental implications. This randomized controlled trial evaluates the impact of Gentle Human Touch (GHT) and rate change (eye mask and earplug) on pain and comfort during heel prick blood collection in premature infants (32-36+6 weeks gestational age). A total of 60 infants were randomly assigned to three groups: GHT, rate change, and standard care (pacifier). Pain was assessed using the Premature Infant Pain Profile-Revised (PIPP-R), and comfort was measured before, during, and after the procedure using the COMFORTneo operator. Physiological impact (heart rate, oxygen saturation) and propagation time were recorded. The findings provide evidence for safe and effective non-pharmacological interventions in pain management and their inclusion in developmental care protocols.

03

Conditions studied

  • Premature
  • Neonatal Intensive Care Unit
  • Touch
  • Nursing Care

Browse trials for

04

Who can participate

Ages eligible
32 Weeks to 37 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants with a gestational age between 32 and 36+6 weeks
  • Written obtained from parents

Exclusion criteria

Exclusion Criteria:

  • Infants with serious medical conditions that may affect study parameters
  • Infants receiving intensive invasive treatments (e.g., opioid or sedative medication)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Gentle Human Touch

    Gentle human touch (GHT) will be applied 3-5 minutes before, during, and after the heel prick blood test.

    Other: Gentle Human Touch

  • Experimental
    Environmental Modification

    Eye mask and earmuffs will be applied 3-5 minutes before, during, and after the heel prick blood test.

    Other: Environmental Modification

  • No intervention
    Standard Care

    Finger feeding will be provided before, during, and after the procedure, according to the unit routine.

Interventions

  • OtherGentle Human Touch

    Before starting the procedure, the nurse performing the intervention will wear a clean gown and wash both hands and forearms with an antimicrobial agent for 3 minutes. The nurse's hand temperature will be measured with a digital thermometer prior to the intervention to ensure it is at an appropriate level. If the temperature is not suitable, both hands will be warmed under a radiant warmer until they reach 33-33.2 °C, and the intervention will begin once this temperature is achieved. During the intervention, the nurse will place the fingertips of one hand on the infant's eyebrow line with the palm resting on the top of the head, while the other hand will be positioned on the lower abdomen covering the waist and hips, maintaining this position for 15 minutes.

  • OtherEnvironmental Modification

    Infants assigned to the environmental modification group will receive an eye mask and neonatal earmuffs (Minimuffs) to reduce exposure to light and noise. The eye mask is a soft, adjustable, and disposable phototherapy band designed to block external light stimuli. The earmuffs are oval-shaped, foam-based neonatal ear protectors with hydrogel adhesive, designed to reduce noise levels by more than 50% and ensure safe single use. Both interventions will be applied 3-5 minutes before, during, and for 3-5 minutes after venous blood sampling, for a total of approximately 15 minutes. Standard care with a pacifier will also be provided according to unit practice.

06

What researchers measure

Primary outcomes

  1. Procedural Pain Score

    The pain experienced during heel prick blood sampling will be assessed using the Premature Infant Pain Profile-Revised (PIPP-R) scale. The scale ranges from 0 to 21 (for premature infants), with higher scores indicating greater pain intensity.

    Time frame: 5 minutes before the procedure, during the procedure, and 5 minutes after the procedure.

  2. Procedural Comfort Score

    Comfort during heel prick blood sampling will be assessed using the COMFORTneo Scale. The scale ranges from 7 to 35, with higher scores indicating a lower level of comfort.

    Time frame: 5 minutes before the procedure, during the procedure, and 5 minutes after the procedure.

Secondary outcomes

  1. Crying Duration

    Total duration of crying during heel prick blood sampling will be measured with a stopwatch and recorded in seconds.

    Time frame: During and immediately after heel prick blood sampling

  2. Oxygen Saturation

    Oxygen saturation levels will be monitored with pulse oximetry.

    Time frame: 5 minutes before, during, and 5 minutes after heel prick blood sampling

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 5 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Jul 20, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07715682
Lead sponsor
Kubra Nur Kabakcı Sarıdağ
Responsible party
Kubra Nur Kabakcı Sarıdağ (Research Assistant Kubra Nur Kabakcı Sarıdağ, Baskent University) — Sponsor-investigator
First posted
Jul 20, 2026
Start date
Apr 20, 2026
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 16, 2026

Study contacts

Kubra Nur N KABAKCI SARIDAĞ, RN, MSc
Contact
kubranurkabakci@gmail.com
+905079149033

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion